proxyvotesnow.com

Home › Companies › 10x Genomics, Inc. › 2025-2026

10x Genomics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and 10x Genomics, Inc.’s Form 8-K, filed 2026-06-08 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Ballot items
  • 315Asset managers
  • 1,784Fund votes
  • 2026-06-04Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore 10x Genomics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by 10x Genomics, Inc.

These tallies are 10x Genomics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-08 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

10x Genomics, Inc. — official shareholder meeting results, meeting held 2026-06-04
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Serge Saxonov 164,137,38115,559,860557,329 --18,560,948 Majority: yes
Elect Director: Benjamin J. Hindson 162,942,76616,761,532550,270 --18,560,950 Majority: yes
Elect Director: John R. Stuelpnagel 155,628,36524,072,179554,023 --18,560,951 Majority: yes
Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year 197,719,939458,231637,346 ---- Majority: yes
Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as descr 176,677,5402,828,730748,296 --18,560,952 Majority: yes

Source: 10x Genomics, Inc., Form 8-K, filed with the SEC on 2026-06-08 — read the filing on EDGAR.

How asset managers voted at the 10x Genomics, Inc. 2025-2026 meeting

Each item below shows how the 315 asset managers that disclosed a 10x Genomics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 14 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 176,677,540AGAINST: 2,828,730

10x Genomics, Inc.’s own tally for this item (“Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executi”): 176,677,540 for, 2,828,730 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 314 asset managers below cast 96% of the shares they voted on this item FOR (103,211,890 for, 4,154,289 against).

FOR 95%
FOR: 103,211,890 (95.5%)AGAINST: 4,154,289 (3.8%)ABSTAIN: 740,221 (0.7%)NOT VOTED: 733 (0.0%)
Largest asset managers voting on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity34,253,4290 00For
Vanguard13,119,7733 00For
ARK ETF Trust9,942,3480 00For
BlackRock7,411,9460 00For
Amova Asset Management Co., Ltd.5,090,3950 00For
Capital Group02,904,600 00Against
GEODE CAPITAL MANAGEMENT, LLC2,904,4160 00For
T. Rowe Price2,234,5250 00For
Charles Schwab2,229,4570 00For
State Street2,152,1900 00For
JACOBS LEVY EQUITY MANAGEMENT, INC1,148,5790 00For
Blue Water Life Science Advisors, LP1,089,9750 00For
Goldman Sachs1,046,8480 00For
AQR985,1070 00For
Northern Trust877,3750 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC807,9280 00For
Russell Investments807,8820 00For
Nuveen802,5810 00For
ARK Investment Management LLC743,5960 00For
Dimensional655,8330 00For
Federated Hermes596,7770 00For
Freshford Capital Management, LLC587,1490 00For
American Century0584,108 00Against
STATE OF MICHIGAN RETIREMENT SYSTEM572,9250 00For
Janus Henderson512,0280 00For

Showing the 25 largest of 314 asset managers. See all 314 in the interactive database.

2. Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: Benjamin J. Hindson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%
FOR: 162,942,766AGAINST: 16,761,532

10x Genomics, Inc.’s own tally for this item (“Elect Director: Benjamin J. Hindson”): 162,942,766 for, 16,761,532 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 78 asset managers below cast 94% of the shares they voted on this item FOR (49,127,161 for, 3,203,209 against).

FOR 94%
FOR: 49,127,161 (93.9%)AGAINST: 3,203,209 (6.1%)ABSTAIN: 10,077 (0.0%)
Largest asset managers voting on “Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expir” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,850,1580 00For
Vanguard12,122,04210,367 20For
ARK ETF Trust9,942,3480 00For
BlackRock4,178,5910 00For
Capital Group1,452,3000 00For
Charles Schwab1,113,6940 00For
T. Rowe Price31,337661,961 00Against
Dimensional0484,869 00Against
TIAA403,5020 00For
Pacific Life382,1180 00For
JPMorgan375,2910 00For
Russell Investments367,0390 00For
Goldman Sachs361,9470 00For
Simplify Exchange Traded Funds348,3570 00For
Equitable234,06485,300 00For
Nationwide33,983259,317 00Against
American Century0291,528 00Against
Columbia Threadneedle256,0510 00For
Janus Detroit Street Trust0250,930 00Against
Principal Exchange-Traded Funds0224,706 00Against
AMERICAN BEACON FUNDS183,1650 00For
QUANTITATIVE MASTER SERIES LLC179,2520 00For
Nuveen176,7140 00For
ARK Venture Fund146,8690 00For
Lincoln Financial100,67742,185 00For

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

3. Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: John R. Stuelpnagel

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%
FOR: 155,628,365AGAINST: 24,072,179

10x Genomics, Inc.’s own tally for this item (“Elect Director: John R. Stuelpnagel”): 155,628,365 for, 24,072,179 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 78 asset managers below cast 87% of the shares they voted on this item FOR (45,696,450 for, 6,633,920 against).

FOR 87%13%
FOR: 45,696,450 (87.3%)AGAINST: 6,633,920 (12.7%)ABSTAIN: 10,077 (0.0%)
Largest asset managers voting on “Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expir” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity13,360,2512,489,907 00For
Vanguard12,115,92616,483 20For
ARK ETF Trust9,942,3480 00For
BlackRock4,178,5910 00For
Capital Group1,452,3000 00For
Charles Schwab1,113,6940 00For
T. Rowe Price31,337661,961 00Against
Dimensional0484,869 00Against
TIAA0403,502 00Against
Pacific Life382,1180 00For
JPMorgan375,2910 00For
Russell Investments367,0390 00For
Goldman Sachs361,9470 00For
Simplify Exchange Traded Funds348,3570 00For
Equitable189,160130,204 00For
Nationwide33,983259,317 00Against
American Century0291,528 00Against
Columbia Threadneedle256,0510 00For
Janus Detroit Street Trust0250,930 00Against
Principal Exchange-Traded Funds0224,706 00Against
AMERICAN BEACON FUNDS183,1650 00For
QUANTITATIVE MASTER SERIES LLC179,2520 00For
Nuveen0176,714 00Against
ARK Venture Fund146,8690 00For
Lincoln Financial26,177116,685 00Against

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

4. Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: Serge Saxonov

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%
FOR: 164,137,381AGAINST: 15,559,860

10x Genomics, Inc.’s own tally for this item (“Elect Director: Serge Saxonov”): 164,137,381 for, 15,559,860 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 78 asset managers below cast 95% of the shares they voted on this item FOR (49,924,039 for, 2,466,331 against).

FOR 95%
FOR: 49,924,039 (95.3%)AGAINST: 2,466,331 (4.7%)ABSTAIN: 10,077 (0.0%)
Largest asset managers voting on “Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expir” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,850,1580 00For
Vanguard12,122,04510,364 20For
ARK ETF Trust9,942,3480 00For
BlackRock4,178,5910 00For
Capital Group1,452,3000 00For
Charles Schwab1,113,6940 00For
T. Rowe Price693,2980 00For
Dimensional0484,869 00Against
TIAA403,5020 00For
Pacific Life382,1180 00For
JPMorgan375,2910 00For
Russell Investments367,0390 00For
Goldman Sachs361,9470 00For
Simplify Exchange Traded Funds348,3570 00For
Equitable234,06485,300 00For
Nationwide33,983259,317 00Against
American Century0291,528 00Against
Columbia Threadneedle256,0510 00For
Janus Detroit Street Trust0250,930 00Against
Principal Exchange-Traded Funds0224,706 00Against
AMERICAN BEACON FUNDS183,1650 00For
QUANTITATIVE MASTER SERIES LLC179,2520 00For
Nuveen176,7140 00For
ARK Venture Fund146,8690 00For
Lincoln Financial100,67742,185 00For

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

5. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 197,719,939AGAINST: 458,231

10x Genomics, Inc.’s own tally for this item (“Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the C”): 197,719,939 for, 458,231 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 78 asset managers below cast 100% of the shares they voted on this item FOR (52,330,369 for, 0 against).

FOR 99.9%
FOR: 52,330,369 (100.0%)ABSTAIN: 10,077 (0.0%)
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,850,1580 00For
Vanguard12,132,4080 20For
ARK ETF Trust9,942,3480 00For
BlackRock4,178,5910 00For
Capital Group1,452,3000 00For
Charles Schwab1,113,6940 00For
T. Rowe Price693,2980 00For
Dimensional484,8690 00For
TIAA403,5020 00For
Pacific Life382,1180 00For
JPMorgan375,2910 00For
Russell Investments367,0390 00For
Goldman Sachs361,9470 00For
Simplify Exchange Traded Funds348,3570 00For
Equitable319,3640 00For
Nationwide293,3000 00For
American Century291,5280 00For
Columbia Threadneedle256,0510 00For
Janus Detroit Street Trust250,9300 00For
Principal Exchange-Traded Funds224,7060 00For
AMERICAN BEACON FUNDS183,1650 00For
QUANTITATIVE MASTER SERIES LLC179,2520 00For
Nuveen176,7140 00For
ARK Venture Fund146,8690 00For
Lincoln Financial142,8620 00For

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Largest 10x Genomics, Inc. shareholders voting in 2025-2026

Ranked by the number of 10x Genomics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 127,691,329 shares outstanding at the time of that meeting.

Top 10x Genomics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 26.83%
2Vanguard 10.27%
3ARK ETF Trust 7.79%
4BlackRock 5.80%
5Amova Asset Management Co., Ltd. 3.99%
6Capital Group 2.27%
7GEODE CAPITAL MANAGEMENT, LLC 2.27%
8T. Rowe Price 1.75%
9Charles Schwab 1.75%
10State Street 1.69%

Reported 10x Genomics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

10x Genomics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 13.89% 13F
T. Rowe Price Associates, Inc. 11.00% 13G
Vanguard Group 10.19% 13F
BlackRock 7.89% 13F
ARK Investment Management LLC 7.83% 13G
Vanguard Portfolio Management 5.47% 13G
Goldman Sachs 3.22% 13F
Morgan Stanley 2.50% 13F
State Street 2.03% 13F
Dimensional Fund Advisors 1.60% 13F

Percentages above are of 127,691,329 shares outstanding, as reported by 10x Genomics, Inc. on its Form 10-K dated 2025-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 10x Genomics, Inc.’s 10-K dated 2025-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At 10x Genomics, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 315 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,784 separate fund positions. On the most widely held item on that ballot — A vote to approve, on a non-binding, advisory basis, the compensation of our named executive… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: 10x Genomics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-08.

10x Genomics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).